Biotech Startups

SUDx-Biotec develops sugar chain-based diagnostic technologies and solutions. The company operates in the biotech sector, headquartered in Kagoshima, Japan.

1 investor

Sugarlogix develops functional food products designed to support disease management, particularly for diabetes and metabolic health, through innovative ingredients and scientific advancement in food technology.

1 investor

Sungwun Pharmacopia develops active pharmaceutical ingredients (APIs) and biopharmaceutical drugs, including antiviral compounds such as remdesivir and favipiravir, which it manufactures and licenses to pharmaceutical partners. The company also works on microbiome-related technology and has partnered with Indonesian pharmaceutical firm PT. Kimia Farma.

1 investor

Sunra Health is a pediatric health platform that gives families personalized genetic insights along with vaccine decision support, wellness forecasting, symptom tracking, and ongoing guidance from birth through childhood. It combines clinical research and technology to help parents and healthcare providers make more informed decisions about a child's health.

1 investor

Supermag manufactures magnetic levitation motors, fluid transport systems, and vacuum solutions for semiconductor, biopharmaceutical, chemical, and energy industries. The company provides high-purity, low-shear equipment designed to meet demanding manufacturing and processing requirements across multiple industrial sectors.

1 investor

Supermoon Capital is a venture investor focused on companies working in sleep and circadian science, backing scientists, technologists, and creatives building products around sleep health and biological rhythms. It targets consumer and biotech opportunities in the emerging sleep-technology market.

1 investor

Supernus is a pharmaceutical company that develops and markets products in the biosciences and pharmaceutical industry. This page lists awards and recognitions the company has received for growth, workplace, and performance.

1 investor

Suraksha operates a network of diagnostic and healthcare centres across eastern India offering pathology, genomics, radiology and imaging, and specialty clinics, along with home sample collection and doctor consultation services. It serves patients through owned centres, public-private partnerships, and franchisees primarily in West Bengal, Bihar, Assam, and Jharkhand.

1 investor

Surfix develops diagnostic tests based on surface modification and organic chemistry technologies, offering accessible and easy-to-use solutions for early diagnosis and monitoring of medical conditions. The company operates as a spin-off from Wageningen University & Research's organic chemistry department.

1 investor

SURGE develops clinical approaches for cancer immunotherapy and post-surgical cancer recurrence prevention. The company applies bioengineering and drug delivery innovations to address unmet oncology needs.

1 investor

Company operating a biomarker discovery platform (Stabl) that applies multiomics, systems biology, and machine learning to extract clinically actionable biomarkers from complex datasets. Its product PreCyte SSI predicts the risk of postoperative surgical complications to help clinicians personalize perioperative care in hospitals.

1 investor

SurgiBox develops surgical technology co-developed with users to enable safe surgery for patients and healthcare providers, focused on delivering safe surgical care regardless of location. The company builds medical devices aimed at solving challenges in surgical care globally.

1 investor

Surphage develops specific bacteriophage combinations (branded NeoPhage) to control pathogenic bacteria such as Salmonella, Escherichia coli, and Listeria monocytogenes in animal and plant production without the use of antibiotics. Its powdered, easy-to-apply antimicrobial products serve the livestock, agriculture, and food-processing industries.

1 investor

1 investor

Clinical-stage company developing next generation antibody drug conjugates for cancer treatment using proprietary cell-free protein manufacturing technology.

1 investor

Svastia is a clinical-genomic platform that uses genetic screening to improve cancer therapy outcomes for pharmaceutical companies and hospitals. The platform bundles contract research services with bioinformatics analysis, and coordinates a distributed network of laboratory service providers to support drug development, clinical trial patient selection, and personalized treatment recommendations.

1 investor

SwabBot manufactures automated robotic swabbing devices (SWAB-E and SWAB-B) for cleaning validation in life sciences manufacturing, reducing confined space entry risks and improving consistency in pharmaceutical and biotech facility validation testing.

1 investor

Swan Neck Bio produces DIRINOC, a ready-to-use, quality-certified starter culture (inoculum) developed from a client's own microbial strain for use in fermentation and biomanufacturing. It applies single-use bioreactor (FlexCell) technology and an AI-assisted development program to create stable, concentrated seed cultures of yeasts, filamentous fungi, and other microbes for biomanufacturers.

1 investor

1 investor

Swift Innovations develops science-backed personal-care and cosmetic products, taking formulations from research and lab stages through to market. It focuses on high-performance skincare and cosmetic solutions with an emphasis on safety, efficacy, and sustainable innovation for global markets.

1 investor

Digital therapeutics developer behind Stanza, an FDA-authorized smartphone behavioral therapy for fibromyalgia symptoms.

1 investor

Swiss Decode develops portable DNA detection devices that deliver results in under an hour, enabling evidence collection at the point of need without external laboratory testing.

1 investor

Swixx BioPharma is a specialized pharmaceutical distributor and market access partner that represents international biopharma, OTC, and medical device companies in markets across Central & Eastern Europe, the Middle East, North Africa, Latin America, and Eurasia. The company operates as an indirect route-to-market solution for healthcare companies seeking regional expansion without establishing their own subsidiaries.

1 investor

Syenex provides cell delivery technologies and contract development services for therapeutic cell engineering, serving biopharmaceutical companies developing cell-based therapies. The company integrates cell engineering and delivery capabilities with regulatory support for clinical development.

1 investor